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Abstract
Heat shock protein 70 (HSP70) has been implicated in infection-related processes and has been found in body fluids during
infection. This study aimed to determine whether pleural mesothelial cells release HSP70 in response to bacterial infection in
vitro and in mouse models of serosal infection. In addition, the in vitro cytokine effects of the HSP70 isoform, Hsp72, on
mesothelial cells were examined. Further, Hsp72 was measured in human pleural effusions and levels compared between
non-infectious and infectious patients to determine the diagnostic accuracy of pleural fluid Hsp72 compared to traditional
pleural fluid parameters. We showed that mesothelial release of Hsp72 was significantly raised when cells were treated with
live and heat-killed Streptococcus pneumoniae. In mice, intraperitoneal injection of S. pneumoniae stimulated a 2-fold
increase in Hsp72 levels in peritoneal lavage (p,0.01). Extracellular Hsp72 did not induce or inhibit mediator release from
cultured mesothelial cells. Hsp72 levels were significantly higher in effusions of infectious origin compared to non-infectious
effusions (p,0.05). The data establish that pleural mesothelial cells can release Hsp72 in response to bacterial infection and
levels are raised in infectious pleural effusions. The biological role of HSP70 in pleural infection warrants exploration.
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Introduction
Bacterial pleural infection is a centuries-old disease and its
global incidence continues to rise [1]. It affects 65,000 patients in
the United Kingdom and United States every year [2], and carries
a mortality as high as 20% [3]. Streptococcus pneumoniae is the leading
bacterial cause of pediatric pleural infection and one of the
commonest in adults [4]. Bacterial pneumonias are complicated
by a simple parapneumonic effusion (PPE) in up to 40% of patients
[5–7]. When secondarily infected, the effusion is characterised by a
low fluid pH and loculation (a complicated PPE) or the presence of
bacteria or frank pus (empyema) [5,6]. The mechanism of post-
pneumonic effusion development remains poorly understood [4].
Heat Shock Proteins (HSPs) are amongst the most abundant
and phylogenetically conserved proteins, present in all sub-cellular
compartments. HSP70 is one of the major HSPs expressed and
includes the constitutive Hsp73 and stress-induced Hsp72 family
members [8]. Although HSPs are traditionally thought to function
as intracellular proteins, their extracellular release and activity is
increasingly evident. In this regard, HSP70 can be released from
both necrotic [9] and viable cells [10–13] in culture and Hsp72 is
known to act as a potent cytokine secretagogue for various cell
types, including monocytes [14], macrophages [15], fibroblast-like
synoviocytes [16] and murine splenocytes [17].
The presence of extracellular HSP70 may have broad
biological significance in pleural infection. HSP70 is present in
various body fluids, including normal serum [18], cerebrospinal
[19,20], synovial [21] and bronchoalveolar lavage fluid [22].
Whether HSP70 is present in pleural fluid, especially in post-
pneumonic effusions, has not been studied. In addition, little is
known about the source of HSP70 within the pleura and the
biological effects of extracellular Hsp72 on mesothelial cells have
not been explored.
The present study is the first to describe the release of Hsp72
from mesothelial cells, particularly its increased release in response
to S. pneumoniae infection in vitro and in vivo, and examine the effect
of extracellular Hsp72 on mesothelial cell cytokine and chemokine
release. Further, this study determined the presence of Hsp72 in
human pleural fluids and describes its elevated levels in patients
with infectious-related effusions.
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Materials and Methods
Ethics statement
Animal experiments were performed on C57BL/6 and BALB/c
mice aged 8–10 weeks (Animal Resources Centre, Perth, Aus-
tralia). This study was carried out in strict accordance with the
recommendations within the ethics application approved by the
Animal Ethics Committee of the University of Western Australia
(Permit number 03/100/905). All efforts were made to minimize
animal suffering. Animals were anesthetized with methoxyflurane
before cervical dislocation. For the use of human serum and
pleural fluid samples, the Ethics Committees of Sir Charles
Gairdner Hospital and Hollywood Hospital (Western Australia),
the Mid- and South-Buckinghamshire and Central Oxford (UK)
and the Arnau de Vilanova University Hospital (Spain) Research
Ethic Committees approved the collection of the samples and all
participants provided written informed consent.
Mesothelial Cells
Primary murine mesothelial cells were harvested from the
omentum of C57BL/6 mice and cultures established as previously
described [23]. Primary culture of human pericardial mesothelial
cells were obtained as previously described [24]. The SV40-
transformed human mesothelial MeT-5A cell line was purchased
from the American Tissue Culture Collection (Manassas, VA,
USA). Cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 4 mM L-glutamine,
0.2 mg/ml streptomycin, 0.2 mg/ml penicillin and fetal calf serum
(FCS) at 15% (v/v) for primary cultured cells and 10% (v/v) for
MeT-5A.
Bacterial strains and culture
S. pneumoniae 262 (serotype 19F; ATCC #49619), TIGR4
(serotype 4; ATCC #BAA-334) and D39 (serotype 2) strains were
used in this study. The 262 and TIGR4 strains were stored in
Heart Brain Infusion Broth containing 15% (v/v) glycerol at
280uC and directly sub-cultured onto Blood agar plates for 18 hr
at 37uC in 5% (v/v) CO2. Following this, suspensions were
prepared in 0.85% (w/v) saline to a turbidity of 0.5 McFarland
using an Oxoid Turbidometer (Thermo Scientific; Victoria,
Australia). The 262 and TIGR4 strains were also subject to
heat-killing at 95uC for 45 min. Viability of the live bacteria and
successful heat-killing were verified by plate counts. Briefly, ten-
fold dilutions of each bacteria ranging from 1021 to 1026 colony
forming units (CFU)/ml were prepared in saline, with 20 ml
spotted onto blood agar plates, and incubated overnight at 37uC.
The following day, the number of CFU per 20 ml was counted and
the CFU/ml calculated. The D39 strain was kindly provided by
Dr Lea-Ann Kirkham (School of Paediatrics and Child Health,
University of Western Australia) and were cultured on blood agar
plates at 37uC over night under anaerobic conditions using the BD
GasPakTM EZ Anaerobic Pouch System (BD Diagnostics,
Australia). Colonies were inoculated into the relevant media,
grown to mid-log phase (OD600 nm 0.55-0.65) and counted using a
Helber bacteria counting chamber (ProSciTech; Queensland,
Australia). Heat-inactivated FCS was added to the mid-log phase
culture at a concentration of 20% (v/v) and stored at 280uC.
Before experimentation, the D39 strain was thawed, washed and
prepared to the appropriate concentration in saline.
Immunocytochemistry
Immunocytochemistry was performed as previously described
[23] using antibodies raised against Hsp72 or Hsp73 (Santa Cruz
Biotechnology; Santa Cruz, CA, USA). Cells were counterstained
in hematoxylin and Scott’s tap water.
Quantification of Hsp72 protein
The stressed-induced Hsp72 isoform in serum samples, pleural
effusions and culture supernatants was measured using the Total
HSP72/HSPA1A DuoSet IC ELISA kit, according to the
manufacturer’s instructions (R&D Systems; Minneapolis, MN,
USA).
Stimulation of mesothelial cells
For all experiments, cells were grown to confluence in 24-well
plates and deprived of serum 24 hr prior to stimulation. For
bacterial stimulations, cells were washed with antibiotic-free media
and incubated with live or heat-killed S. pneumoniae 262 or TIGR4
(105, 106 and 107 CFU/ml) for 2, 4, 6 and 24 hr. In separate
experiments, cells were stimulated with a low-endotoxin, purified
recombinant preparation of human Hsp72 (0.1–5 mg/ml) for
24 hr (Enzo Life Science; Farmingdale, NY, USA). Cells treated
with 10 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich) were included as a positive control of cytokine release. In
other studies, cells were pre-treated with Hsp72 (1 mg/ml) for 2 hr,
washed and stimulated with TNF-a (5 ng/ml) (eBioscience; San
Diego, CA, USA) or thrombin (1 U/ml) (Sigma-Aldrich; St Louis,
MO, USA) for an additional 24 hr. Following all stimulations, the
supernatants were collected and stored at 220uC until required.
Determination of cytokine release
Monocyte chemotactic protein (MCP)-1, interleukin (IL)-10,
TNF-a, interferon (IFN)-c (eBioscience) and VEGF (R&D
Table 1. Baseline patient characteristics.




Subjects, n 40 36 48 54 54 23 18
Age, yr 82 (73–87)+ 75 (66–82) 35 (28–44)* 54 (40–71) 62 (43–80) 70 (51–75) 70 (59–61) ,0.001
Male sex, n 23 (58) 17 (47) 33 (69) 30 (56) 38 (70) 15 (65) 11 (61) 0.308
Hsp72, ng/mL 7 (4–13)* 13 (5–26)* 21 (10–38) 27 (11–161) 23 (12–72) 18 (10–356) 17 (11–23) ,0.001
Data are presented as median (quartile range) or n (%).
+Significantly higher than the respective values in other groups by post-hoc test.
*Significantly lower than the respective values in other groups by post-hoc test.
doi:10.1371/journal.pone.0063873.t001
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Systems) levels in culture supernatants were determined using
ELISAs, following the manufacturer’s instructions.
Murine intraperitoneal challenge with S. pneumoniae D39
strain
BALB/c mice (n = 11) were given a single intraperitoneal
injection of live S. pneumoniae D39 (,16107 CFU in 0.1 ml of
saline) or saline as a control. The viability and quantity of
challenge doses were verified by parallel plate count. Mice were
monitored and sacrificed by cervical dislocation at 7 and 17 hours
post-injection and the peritoneal cavity was lavaged with 1 ml
PBS. The lavage was centrifuged at 2006g for 10 min and the
supernatant collected for quantification of Hsp72 protein (de-
scribed above).
Human pleural fluid and serum samples
Patient samples were obtained from three cohorts. Transudative
and exudative effusions were defined by Light’s criteria [25]. A
malignant pleural effusion was defined by the presence of cancer
cells on histocytologic examination of the pleural fluid or tissue
biopsies. Tuberculous pleural effusion was defined by the presence
of Mycobacterium tuberculosis on culture of pleural fluid, sputum, or
pleural tissue, and/or demonstration of typical caseating granu-
lomas on pleural biopsies. Parapneumonic effusions referred to
those associated with pneumonia and were subdivided into three
groups: UPPE (resolution with antibiotics alone), CPPE (non-
purulent effusions which required chest tube drainage), and
empyema (presence of bacteria and/or pus in the pleural cavity).
To compare the systemic and pleural fluid levels of Hsp72,
blood and pleural fluid samples from 20 patients with malignant
effusions and 20 with benign pleural effusions were randomly
selected from the Australian Mesothelioma Tissue Bank, a
member bank of the Australian Biospecimen Network-Oncology,
which is supported in part by an NHMRC enabling grant [26].
The malignant effusion group included patients with malignant
mesothelioma (n = 10), lung cancer (n = 4), breast cancer (n = 3)
and leukemia/lymphoma (n = 3). Patients with benign effusions
were tracked or followed-up until death or to last citation in the
Public Health database system (Western Australia) and none had
developed any pleural malignancies.
The levels of Hsp72 in different types of pleural effusions were
tested in two separate cohorts. Firstly, a cohort of 273 pleural fluid
samples randomly selected from a biobank of pleural fluid samples
from patients undergoing diagnostic thoracenteses at the Arnau de
Vilanova University Hospital (Lleida, Spain). This included 131
effusions related to bacterial infection (54 UPPE, 54 CPPE and 23
empyema), 48 tuberculous effusions, 36 malignant effusions, 18
other exudates and 40 transudates (34 congestive heart failures
and 6 hepatic hydrothoraces) (Table 1).
The results were further verified in a validation cohort
comprising pleural fluid prospectively collected from patients
(n = 243) presenting with pleural effusions for diagnosis/manage-
ment at the Oxford Pleural Unit (Oxford, UK), as reported
previously [27]. In brief, this cohort included 243 patients,
including 36 effusions related to bacterial infections (9 UPPE, 1
CPPE and 26 empyema), 3 tuberculosis effusions, 151 malignant
Figure 1. Mesothelial cells express Hsp72 and Hsp73 on the cell surface. Non-permeabilised mesothelial cells were assessed for expression
of cell surface-associated HSP70 proteins by immunocytochemistry. The constitutive Hsp73 and stress-induced Hsp72 forms were examined
separately. The figures are representative of three independent experiments. Bar = 20 mm.
doi:10.1371/journal.pone.0063873.g001
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pleural effusions, 37 others exudates and 16 transudates (12
congestive heart failures and 4 hepatic hydrothoraces).
Statistical analysis
Data are presented as mean 6 standard error of the mean
(SEM and median (range), where appropriate. A p value of ,0.05
was considered statistically significant.
The differences among groups were compared by one-way
analysis of variance (ANOVA) on-ranks with multiple comparisons
between groups performed using Dunn’s post hoc test. Student’s t
test with Bonferroni correction and Wilcoxon Rank Sum Test
were used to compare differences between two treatment groups
for parametric and non-parametric data, respectively. Paired t test
was used to compare differences between matched serum and
pleural fluid samples. The discriminative properties of Hsp72 were
evaluated using receiver operating characteristics (ROC) curve
analysis, selecting cut-off values with more than 80% specificity for
infectious effusions. Measures of diagnostic accuracy (sensitivity,
specificity, likelihood ratios (LR)) of pleural fluid Hsp72 for
differentiating effusions of infective causes (PPE and empyema)
from those of non-infective etiologies, PPE vs non-PPE, and CPPE
vs UPPE, were calculated. Analyses were conducted using
statistical softwares: SPSS v18.0 (Chicago, IL, USA) and
GraphPad Prism 4.0 (La Jolla, CA, USA).
Results
Mesothelial cells express HSP70
Using non-permeabilised mesothelial cells, we demonstrated for
the first time that mesothelial cells are a source of both the
constitutive Hsp73 and stress-induced Hsp72 isoforms of HSP70.
All human and murine mesothelial cells tested expressed Hsp73
and Hsp72, as judged by immunocytochemistry. The total cell
population of each mesothelial cell type stained for Hsp73 and
Hsp72. For MeT-5A cells, Hsp72 immunoreactivity was greater
compared to Hsp73, whereas Hsp73 staining was more intense for
the primary mesothelial cell types tested (Figure 1).
Live and heat-killed S. pneumoniae induce Hsp72 release
from mesothelial cells in vitro
MeT-5A cells were treated with live or heat-killed S. pneumoniae
strains and released Hsp72 measured in culture supernatants by
ELISA. Hsp72 was released from cultured MeT5A mesothelial
cells at all time points examined. Live S. pneumoniae 262 and
TIGR4 both induced Hsp72 release from mesothelial cells
(p,0.05) (Figures 2a and 2c). The stimulation of Hsp72 release
was still observed for both S. pneumoniae strains even when the
bacteria were heat-killed before experimentation, but, to a lesser
extent (Figures 2b and 2d).
Figure 2. Pleural mesothelial cells release Hsp72 in response to infection with Streptococcus pneumoniae. MeT-5A cells were treated with
live (A and C) or heat-killed (B and D) Streptococcus pneumoniae 262 strain (A and B) and S. pneumoniae TIGR4 strain (C and D) and Hsp72 levels
measured in culture supernatants at various time points up to 24 hr by ELISA. Significant release of Hsp72 was observed at all time points examined
(p,0.05) and was still evident following treatment with heat-killed S. pneumoniae. * Denotes significantly higher than vehicle control cells (p,0.05).
The data are presented as the mean 6 SEM of three independent experiments performed in triplicate.
doi:10.1371/journal.pone.0063873.g002
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Hsp72 does not induce selected cytokine release from
pleural mesothelial cells
The stress-induced Hsp72 isoform can induce cytokine release
in some cell types [14], and paradoxically inhibit cytokine-induced
mediator release from others [28]. Its ability to do so in mesothelial
cells has not been tested. MeT-5A cells were, therefore, stimulated
with highly purified recombinant Hsp72 and the supernatant was
measured for cytokine release. In contrast to PMA treatment,
Hsp72 stimulation had no effect on mesothelial cell release of
MCP-1 and VEGF (Figure 3a and 3b) or TNF-a, IL-10 and IFN-c
(data not shown). Pre-treatment of MeT-5A cells with Hsp72 did
not change TNF-a- or thrombin-induced MCP-1 levels released
from MeT-5A cells (Figures 3c and 3d).
S. pneumoniae induced Hsp72 release in vivo
To further confirm that bacterial infection contributes to Hsp72
release in serosal cavities lined by mesothelial cells, mice were
injected intraperitoneally with live S. pneumoniae D39. A 2-fold
increase in Hsp72 concentrations were found in the peritoneal
lavage of mice treated with S. pneumoniae D39 over saline controls
at 7 hr post-injection (p = 0.0087). A similar increase in Hsp72
levels was observed at 17 hr post-injection, with the peritoneal
lavage Hsp72 levels being ,2.5-fold higher in mice injected with
D39 (p = 0.0079) (Figure 4).
Hsp72 levels in patients with bacterial pleural infection
To further confirm that Hsp72 was released by pleural
mesothelial cells in response to bacterial pleural infection three
patient cohorts were used. First, systemic and pleural Hsp72 levels
were compared in an Australian cohort. Second, in a Spanish
cohort Hsp72 levels in infectious and non-infectious patients were
determined and the diagnostic accuracy of pleural fluid Hsp72
compared to traditional pleural fluid parameters. Third, these
results were further verified using a UK cohort.
Hsp72 was detected in all human pleural fluids obtained from
patients in all three cohorts (combined n = 536). In contrast,
Hsp72 was detectable in the sera of only 15 of the 20 patients
tested. The median Hsp72 concentration was 7.25 fold higher in
pleural fluid compared to serum (3.6 vs. 0.49 ng/ml; p,0.0001).
Pleural fluid Hsp72 concentration was higher (by up to 300 fold)
than the corresponding serum in the majority (92.5%) of patients
Figure 3. Extracellular Hsp72 does not induce or inhibit cytokine release from pleural mesothelial cells. The ability of a highly purified,
recombinant Hsp72 preparation to induce inflammatory cytokine release from pleural mesothelial cells was determined (A and B). MeT-5ACells were
treated with the indicated doses of Hsp72 or PMA as a positive control, and MCP-1 (A) and VEGF (B) release measured 24 hr post-treatment by ELISA.
In separate experiments, the anti-inflammatory effects of extracellular Hsp72 were examined (C and D). Cells were pre-treated with Hsp72 for 2 hr,
followed by treatment with TNF-a (C) or thrombin (D) for an additional 24 hr to induce MCP-1 release. In contrast to PMA stimulated MeT-5A cells,
treatment with Hsp72 had no impact on cytokine release. The data are presented as the mean 6 SEM of three independent experiments performed
in triplicate. NS, not significant.
doi:10.1371/journal.pone.0063873.g003
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tested (Figure 5a). These findings were consistent with a cellular
source of Hsp72 from within the pleural cavity.
Pleural fluids Hsp72 levels were compared among patients with
infective and non-infective effusions in the Spanish cohort. The
median pleural fluid Hsp72 concentrations were higher in
exudates compared to transudates (21.2 vs 6.5 ng/ml, p,0.0001)
(Figure 5b). Pleural fluid Hsp72 levels were significantly higher in
patients with infection-related pleural effusions (PPE and empy-
ema) over those with non-infective etiologies (23 vs 10.8 ng/ml,
p,0.0001) (Figure 6a). This finding remained robust if tubercu-
lous effusions were included in the infectious group over the non-
infectious group (22.9 vs 10.8 ng/ml, p,0.0001). When analysed
separately, the PPE and empyema groups had significantly
elevated Hsp72 levels compared to the non-infective effusion
group (p,0.001 and p,0.01, respectively). However, no signifi-
cant difference in pleural fluid Hsp72 was observed between PPE
and empyema patients (Figure 6b). Similar results were obtained
when pleural fluid Hsp72 levels were measured in the UK cohort.
The median pleural fluid Hsp72 levels were higher in exudates
compared to transduates by approximately 1.8-fold (p = 0.041).
Pleural fluid Hsp72 levels were elevated in patients with infection-
related effusions (PPE and empyema) compared to non-infective
etiologies by 1.5-fold (p = 0.02) and were the highest in patients
with empyema (p,0.05).
The value of pleural fluid Hsp72 to discriminate between
infection-related effusions and those of non-infective etiologies was
examined in the Spanish cohort. Using a threshold of 40 ng/ml,
pleural fluid Hsp72 could help separate infection-related effusions
from non-infective ones or PPE from other etiologies, although the
AUC was modest (0.688 and 0.658 respectively) and was inferior
to conventional biomarkers such as pH, glucose and LDH used for
the differentiation of UPPE and CPPE (Table 2).
Discussion
Although previous reports have demonstrated inducible changes
in HSP70 expression in peritoneal mesothelial cells [29], this is the
first study to show its extracellular release from pleural mesothelial
cells upon bacterial stimulation in vitro and in vivo. The findings
were further confirmed in three cohorts of human pleural fluid
samples, which showed significantly elevated Hsp72 levels in
infection-related effusions. Although our data suggests the
extracellular release of Hsp72 contributes to the elevated pleural
fluid levels in infection-related effusions, it is possible that impaired
clearance of Hsp72 from the pleural space can contribute to its
elevated levels in pleural fluid. Our data provide the platform for
future investigations of the role of Hsp72 in the pathophysiology of
bacterial pleural infection.
Pleural infection remains a significant global health problem
with a rising incidence in reports from most regions around the
world [1]. The pathobiology of pleural infection however remains
poorly understood. Mesothelial cells line the pleural, peritoneal
and pericardial cavities and are the most abundant cell type in all
these serosal cavities. Mesothelial cells are biologically active and
Figure 4. Hsp72 levels in peritoneal lavage are elevated
following intraperitoneal injection of mice with Streptococcus
pneumoniae. BALB/c mice were given a single intraperitoneal injection
of live Streptococcus pneumoniae D39 strain (,16107 CFU in 0.1 ml of
saline; n = 11) or saline as a control (n = 10). The peritoneal cavity was
lavaged 7 (n = 6) and 17 hr (n = 5) post-injection with 1 ml PBS for
quantification of Hsp72 protein. The results are presented as the fold-
increase in Hsp72 levels over the mean Hsp72 level in mice injected
with saline alone. An approximately 2- and 2.5-fold increase in Hsp72
was shown peritoneal lavage following infection with S. pneumoniae for
7 and 17 hr, respectively (p,0.01 for both).
doi:10.1371/journal.pone.0063873.g004
Figure 5. Hsp72 levels are elevated in exudative pleural effusions. Hsp72 was measured in human samples by ELISA and levels compared
between pleural fluid and serum (A), and transudates and exudates (B). A) Median Hsp72 levels were significantly elevated in pleural fluid compared
to their matched serum sample (n = 20 for each group) (3.6 vs. 0.49 ng/ml; p,0.0001). B) Median Hsp72 levels were higher in exudates (n = 233)
compared to transudates (n = 40) (21.2 vs 6.5 ng/ml, p,0.0001).
doi:10.1371/journal.pone.0063873.g005
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express a broad range of inflammatory mediators, especially in
response to undesirable infiltrating molecules including microbes
[30].
HSP70 is present in all organisms and, in unstressed conditions,
maintains intracellular protein homeostasis by mediating the
folding and translocation of naı¨ve proteins. Although produced
constitutively, HSP70 is abundantly expressed in response to
various physiological, environmental and pathological stressors
[8]. Bacterial infection is known to be a potent inducer of HSP70
expression in variety of cell types [31,32]. Previous reports have
associated infectious diseases with elevated HSP70 levels in body
fluids, including in plasma of children during septic shock [33], in
cerebrospinal fluid [19] and in seminal plasma of the prostate [34].
However, the presence and biological relevance of HSP70 in
pleural infection and the cellular source of pleural fluid HSP70
have not been clarified. This study demonstrates that pleural
mesothelial cells are a source of extracellular HSP70 in pleural
infection. Why MeT-5A cells demonstrated differential staining of
Hsp72 and Hsp73 is unclear and should be the focus of further
research.
Figure 6. Pleural fluid Hsp72 levels in infection-related and non-infective effusions. Pleural fluids Hsp72 levels were compared among
infection-related and non-infective effusions in the Spanish cohort. A) Median Hsp72 levels were significantly higher in infection-related pleural
effusions compared to effusions of non-infective etiologies (p,0.0001). B) Compared to non-infective effusions, Hsp72 levels were also higher when
in PPE (p,0.001) and empyema (p,0.01).
doi:10.1371/journal.pone.0063873.g006
Table 2. Measures of diagnostic accuracy of pleural fluid Hsp72.
Pleural fluid Hsp72, ng/mL Sensitivity, % Specificity, % LR+ LR- AUC
Infectious vs. Non-infectious
$15 62 (55–69) 62 (52–71) 1.6 (1.2–2.1) 0.62 (0.48–0.79) 0.688 (0.624–0.753)
$20 57 (50–64) 72 (63–80) 2.1 (1.5–2.9) 0.60 (0.48–0.73)
$25 49 (41–56) 82 (73–88) 2.7 (1.7–4.2) 0.63 (0.53–0.74)
$40 31 (25–38) 90 (83–95) 3.3 (1.7–6.3) 0.76 (0.68–0.86)
$50 28 (22–36) 90 (83–95) 3.0 (1.5–5.8) 0.79 (0.71–0.87)
PPE vs. other etiologies
$25 49 (40–57) 72 (64–79) 1.7 (1.3–2.4) 0.71 (0.59–0.87) 0.658 (0.593–0.723)
$30 45 (37–54) 80 (72–85) 2.2 (1.5–3.2) 0.69 (0.58–0.82)
$40 34 (27–43) 86 (79–91) 2.4 (1.5–3.9) 0.76 (0.66–0.88)
$50 33 (25–41) 88 (82–92) 2.7 (1.6–4.6) 0.76 (0.67–0.87)
CPPE vs. UPPE
pH #7.20 63 (50–75) 87 (74–93) 4.7 (2.3–9.7) 0.42 (0.29–0.61) 0.831 (0.75–0.912)
Glucose #60 mg/dL 63 (50–75) 93 (82–97) 8.5 (3.2–22.3) 0.4 (0.28–0.57) 0.826 (0.742–0.909)
LDH $1500 UI/L* 57 (44–70) 81 (69–90) 3.1 (1.7–5.7) 0.52 (0.37–0.73) 0.753 (0.662–0.845)
Hsp72 $40 ng/mL 37 (24–51) 69 (54–80) 0.9 (0.5–1.4) 1.1 (0.8–1.4) 0.55 (0.438–0.66)
Values in parentheses are 95% confidence intervals.
LR, likelihood ratio; AUC, area under ROC curve.
*This figure represents three times the upper normal limit for serum LDH.
doi:10.1371/journal.pone.0063873.t002
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We demonstrated that mesothelial cells produce Hsp72 through
three lines of experiments: in cell culture, in a murine model and
in three human pleural effusion cohorts totaling over 500 patients.
The finding is therefore robust, and is likely to be representative of
peritoneal and pericardial infections. In nearly all patients studied,
pleural fluid Hsp72 concentrations were higher than the corre-
sponding sera, suggesting Hsp72 was largely produced within the
pleural space. As such, our study is the first to demonstrate the
extracellular expression and release of Hsp72 by pleural meso-
thelial cells. Although mesothelial cells are a source of extracellular
Hsp72 within the pleural cavity, Hsp72 release from other cell
types such as neutrophils [35] and monocytes [36] likely
contribute to the overall HSP70 pool within pleural effusions.
Hsp72 release was upregulated from mesothelial cells in
response to S. pneumoniae, whether live or heat-killed. This finding
suggests that bacterial stimulation of Hsp72 release is mediated at
least in part via structural molecules within the bacteria and not
predominantly dependent on secreted bacterial products. It is
noteworthy that prior studies have shown HSP70 release by
necrotic, but not apoptotic, cells [9]. Therefore, the liberation of
intracellular Hsp72 following cell lysis as a result of bacterial
exposure may contribute to the elevated pleural fluid Hsp72
concentrations observed from patients with empyema in whom
mesothelial cell necrosis are common. When cocultured, S.
pneumoniae can induce death of mesothelial cells within 24 hr (data
not shown), a process that can contribute to the increased levels of
extracellular Hsp72 observed. However, increased Hsp72 release
is found when cells were treated with heat-killed bacteria (which
induce minimal cell death) as well as at earlier time points of
infection with live bacteria when no cell death was observed. We
are therefore confident that viable mesothelial cells release Hsp72
in response to bacteria. The precise interactions between bacteria
and mesothelial cells that trigger Hsp72 release was beyond the
scope of this study.
The purpose of the mesothelial release of Hsp72 upon bacterial
infection is unclear. Hsp72 is often described in the past as a
chaperone protein. However, recently extracellular functions have
been attributed to Hsp72 and it is now described as a
‘‘chaperokine’’ to reflect its dual role as a chaperone and cytokine.
Hsp72 is known to elicit intracellular calcium mobilisation [14],
induce NF-kB activity [17] and, most notably, stimulate the
release of pro-inflammatory cytokines [14,37]. We used a highly
purified preparation of Hsp72, but failed to induce cytokine and
chemokine release from mesothelial cells. This may be explained
by recent findings that the in vitro cytokine effects of Hsp72 are due
to molecules bound to Hsp72 or contaminants present in the
preparations used, namely bacterial endotoxin [38–41]. It is also
possible that higher concentrations of Hsp72 are required to
induce pro-inflammatory cytokine release from mesothelial cells,
as seen in macrophages [42]. Further, Hsp72 may act on other
(e.g. inflammatory) molecules and cells within the pleura directly,
or via paracrine pathways, which could coordinate/modulate
pleural inflammation via cytokine crosstalk in the pleural cavity
[43]. In addition, the constitutive Hsp73 isoform has also been
shown to have cytokine effects in vitro [44] and, therefore, may
induce similar responses in mesothelial cells.
In vitro, extracellular Hsp72 has also been shown to act as an
anti-inflammatory mediator inhibiting pro-inflammatory cytokine
release [28]. Further, an anti-inflammatory role has been proposed
in vivo using HSP70 deficient mice [45–47]. Inducible changes in
Hsp72 have been shown to contribute to the resolution of
inflammation in a rat model of carrageenin-induced pleurisy
[48,49]. Thus, contrary to its proposed pro-inflammatory activity,
HSP70 may play an anti-inflammatory role in pleural infection. In
vitro we were unable to demonstrate effect of extracellular Hsp72
on pro-inflammatory cytokine release. The precise biologic effect
of released HSP70 proteins in pleural infection warrants further
investigation.
A chaperone protein may be useful clinically as a biomarker for
pleural disease. In this regard, HSP70 expression of effusion
cytology has been shown to be a prognostic marker of poor
survival in malignant disease [50]. However, our study is the first,
to our knowledge, to assess extracellular HSP70 levels in pleural
fluid. The pleural fluid level of Hsp72 was indeed raised in
infection-related effusions, and showed a graded increase from
simple to CPPE to frank empyema. The discriminatory value of
Hsp72 was, however, inferior to conventional markers (eg pleural
fluid pH). This may be due to a variety of clinical reasons
including that confounding interactions among these markers (all
of which reflects pleural inflammation), timing of collection of fluid
and other patient comorbidity that may influence the Hsp72
levels. Nonetheless, the human fluid Hsp72 data further support
that HSP70 forms part of the mesothelial response to bacterial
invasion of the pleura, and the potent and consistent release of
Hsp72 may have a biologic role rather than acting purely as a
chaperone.
In summary, this study confirms the ‘sufficiency’ of the
mesothelium as a pleural source of extracellular Hsp72 and
provides a rationale for the elevated Hsp72 levels observed in
infectious pleural effusions. We demonstrate for the first time the
extracellular release of Hsp72 in response to live and heat-killed
bacteria from mesothelial cells. Further studies are required to
elaborate on the extracellular functions of HSP70 in pleural
infection.
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